Uptake and use of a vaginal ring containing dapivirine for HIV-1 prevention in African women: an open-label extension study

BACKGROUND: Two Phase III clinical trials showed that use of a monthly vaginal ring containing 25 mg dapivirine was well-tolerated and reduced HIV-1 incidence in women by approximately 30% compared to placebo (3.3 and 4.1 versus 4.5 and 6.1 per 100 person-years). Understanding use of the dapivirine...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet HIV
Hoofdauteurs: Baeten, Jared M., Palanee-Phillips, Thesla, Mgodi, Nyaradzo M., Mayo, Ashley J., Szydlo, Daniel W., Ramjee, Gita, Mirembe, Brenda Gati, Mhlanga, Felix, Hunidzarira, Portia, Mansoor, Leila E., Siva, Samantha, Govender, Vaneshree, Makanani, Bonus, Naidoo, Logashvari, Singh, Nishanta, Nair, Gonasagrie, Chinula, Lameck, Parikh, Urvi M., Mellors, John W., Balán, Iván C., Ngure, Kenneth, van der Straten, Ariane, Scheckter, Rachel, Garcia, Morgan, Peda, Melissa, Patterson, Karen, Livant, Edward, Bunge, Katherine, Singh, Devika, Jacobson, Cindy, Jiao, Yuqing, Hendrix, Craig W., Chirenje, Zvavahera M., Nakabiito, Clemensia, Taha, Taha E., Jones, Judith, Torjesen, Kristine, Nel, Annalene, Rosenberg, Zeda, Soto-Torres, Lydia E., Hillier, Sharon L., Brown, Elizabeth R.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2021
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8038210/
https://ncbi.nlm.nih.gov/pubmed/33539762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(20)30304-0
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items